FEMINAREGUL MENO-FREE
Food supplement declared in France, declaration No 2021-4-1839, decision dated 30 April 2021
FEMINAREGUL MENO-FREE is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- LABORATOIRE NUTRAVANCE
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Comprimé
- Daily dose
- 1 comprimé
- Directions for use
- Prendre 1 comprimé par jour avec un verre d'eau.
- Intended populations
- Femme
- Not recommended for (according to the manufacturer)
- Enfants (moins de 12 ans), Femmes enceintes, Sous antidépresseurs
- Objectives stated by the manufacturer (these are not authorised claims)
- Ménopause
Declaration 306188, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Melissa officinalis L. | Feuille | Extrait sec aqueux | 80 mg |
| Vaccinium macrocarpon Aiton | Fruit | Extrait sec alcoolique | 80 mg |
| Hieracium pilosella L. | Parties aériennes | Extrait sec aqueux | 40 mg |
| Rosmarinus officinalis L. | Feuille | Extrait sec hydroalcoolique | 40 mg |
| Crocus sativus L. | Stigmates | Extrait sec hydroalcoolique | 20 mg |
| Brassica oleracea L. | Graine | Extrait au CO2 supercritique | 3 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Pollen | not declared |
| Oligo-proanthocyanidines | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Picolinate de chrome | Chrome | pas de limite (données insuffisantes) | 25 µg |
| L-méthylfolate de calcium | Folates (vitamine B9) | 1,000 µg | 200 µg |
| Méthylcobalamine | Vitamine B12 | pas d'effet indésirable défini | dose annulée par le Conseil d'État en 2011 |
| Riboflavine | Vitamine B2 (riboflavine) | pas de limite (données insuffisantes) | dose annulée par le Conseil d'État en 2011 |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
| Cholécalciférol | Vitamine D | 100 µg (4,000 UI) | 5 µg (200 UI) |
| Acétate de D-alpha-tocophéryle | Vitamine E | 300 mg | 30 mg |
| Bisglycinate de zinc | Zinc | 25 mg | 15 mg |
Additives
E460, E341, E470b, E464, E570, E551
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Déconseillé aux enfants de moins de 10 ans, aux femmes enceintes et aux personnes sous antidépresseur. Les femmes allaitantes et les personnes ayant une hypothyroïdie ou un traitement de la thyroïde doivent préalablement consulter leur médecin.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Melissa officinalis L.
Read the warning, when it applies and the studies cited
LEMON BALM -MELISSA OFFICINALIS
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Vaccinium macrocarpon Aiton
Read the warning, when it applies and the studies cited
CRANBERRY - VACCINIUM MACROCARPON
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
DRIED CRANBERRY JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Rosmarinus officinalis L.
Read the warning, when it applies and the studies cited
ROSEMARY – ROSMARINUS OFFICINALIS Oral
Route of administration: Oral (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Health Canada monograph dated 29 May 2026
ROSEMARY - ROSMARINUS OFFICINALIS Topical
Route of administration: Topical (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.